IMR Press / FBS / Volume 2 / Issue 2 / DOI: 10.2741/s98

Frontiers in Bioscience-Scholar (FBS) is published by IMR Press from Volume 13 Issue 1 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review

Primary and secondary prevention of liver cancer caused by HBV

Show Less
1 Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Front. Biosci. (Schol Ed) 2010, 2(2), 756–763; https://doi.org/10.2741/s98
Published: 1 January 2010
Abstract

Primary cancer of the liver (hepatocellular carcinoma, HCC) is one of the most common cancers worldwide; HBV is the major cause of HCC. A vaccine that protects against HBV infection was invented in 1969 and is now one of the most commonly used vaccines. National vaccination programs have dramatically reduced the prevalence of HBV infection and carriers, with a concomitant decrease in the incidence of HCC in the vaccine-impacted populations. HBV vaccine is the first widely used cancer prevention vaccine; a second that protects against papilloma virus and cancer of the cervix has recently been introduced. Appropriate treatment of HBV carriers with antivirals can reduce the titers of HBV in their blood and thereby greatly reduce the risk of HCC and chronic liver disease. Further data are required to establish criterion for treatment to enable protocols for medical and prevention programs. There are other viral

caused cancers and an understanding of their pathogenesis is an important future direction for research to reduce the human burden of cancer.

Keywords
Hepatitis B Virus
HBV
HCC
Hepatocellular Carcinoma
vaccine
Primary prevention
Secondary prevention
Prevention by delay
Treatment
Review
Share
Back to top